Press Releases

27/04/2023 OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update

20/04/2023 OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology at the 2023 American Association for Cancer Research (AACR) Annual Meeting

18/04/2023 OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio at the 2023 American Association for Cancer Research Annual Meeting

15/03/2023 OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology at the 2023 American Association for Cancer Research (AACR)

01/03/2023 OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer After Failure to Immunotherapies

22/02/2023 OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology

15/02/2023 OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

03/01/2023 OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023

22/12/2022 OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

16/12/2022 OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the Second Tranche of the Financing Granted by the European Investment Bank

12/12/2022 OSE Immunotherapeutics Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

21/11/2022 OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’

08/11/2022 OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs

03/11/2022 OSE Immunotherapeutics Announces Award for OSE-127's Upcoming Oral Presentation in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

03/11/2022 Servier and OSE Immunotherapeutics announce completion of patient enrollment in the Phase 2a clinical trial of OSE-127/S95011 in primary Sjögren’s syndrome

20/10/2022 OSE Immunotherapeutics Updates on Tedopi®, a Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

12/10/2022 OSE Immunotherapeutics Presents Update on BiCKI®-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences

07/10/2022 OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer

1 2 3 4 5 6 7 8 9 10 11 12 13 14